SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AstraZeneca 3Q Imfinzi Sales Rise 26% to $1.99B

AstraZeneca reported third-quarter Imfinzi sales of $1.99 billion, up 26% at constant currency.

AZN

Story updates

07:32:20 AM UTC
SquawkNews
AstraZeneca reported growth in both attributable profit and revenue for the third quarter of 2026. In conjunction with these results, the company announced a $1.5 billion savings drive intended to support further investment in its drug pipeline. The company also noted that oncology remains a key driver of its segment growth, with specific products like Imfinzi showing strong performance, including a 26% increase in sales at constant currency. Management reiterated its full-year guidance, supported by positive Phase III clinical trial readouts that have strengthened the long-term pipeline outlook.

Related stories